share_log

Syndax Pharmaceuticals Received FDA Orphan Drug Designation on Wednesday for axatilimab for Treatment of Idiopathic Pulmonary Fibrosis

Benzinga Real-time News ·  Apr 8, 2021 17:23

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=807821

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment